

1 Method versatility in RNA extraction-free PCR detection of SARS-CoV-2 in
2 saliva samples

3

4 Orchid M. Allicock[†], Devyn Yolda-Carr[†], Rebecca Earnest[†], Mallery I. Breban[†], Noel Vega[†],
5 Isabel M. Ott[†], Chaney Kalinich[†], Tara Alpert[†], Mary E. Petrone[†], Anne L. Wyllie[†]

6

7 [†]Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New
8 Haven, CT 06510, USA

9

10 [†]Correspondence: Orchid M. Allicock

11 60 College Street, New Haven, CT 06510

12 Phone: +1 (201) 401-4573

13 Fax: +1 (203) 785-7356

14 E-mail: orchid.allicock@yale.edu

15 Original Article

16

17 **Keywords:** SARS-CoV-2, COVID-19, heat inactivation, testing

18

19

20

21 **Abstract**

22 Early in the pandemic, a simple, open-source, RNA extraction-free RT-qPCR protocol for
23 SARS-CoV-2 detection in saliva was developed and made widely available. This
24 simplified approach (SalivaDirect) requires only sample treatment with proteinase K prior
25 to PCR testing. However, feedback from clinical laboratories highlighted a need for a
26 flexible workflow that can be seamlessly integrated into their current health and safety
27 requirements for the receiving and handling of potentially infectious samples. To address
28 these varying needs, we explored additional pre-PCR workflows. We built upon the
29 original SalivaDirect workflow to include an initial incubation step (95°C for 30 minutes,
30 95°C for 5 minutes or 65°C for 15 minutes) with or without addition of proteinase K. The
31 limit of detection for the workflows tested did not significantly differ from that of the original
32 SalivaDirect workflow. When tested on de-identified saliva samples from confirmed
33 COVID-19 individuals, these workflows also produced comparable virus detection and
34 assay sensitivities, as determined by RT-qPCR analysis. Exclusion of proteinase K did
35 not negatively affect the sensitivity of the assay. The addition of multiple heat
36 pretreatment options to the SalivaDirect protocol increases the accessibility of this cost-
37 effective SARS-CoV-2 test as it gives diagnostic laboratories the flexibility to implement
38 the workflow which best suits their safety protocols.

39 Introduction

40 Almost two years after the emergence of SARS-CoV-2, diagnostic testing remains an
41 important mitigation strategy. As outbreaks and testing policies evolve and as screening
42 testing has emerged as a key feature enabling communities to safely re-open, labs have
43 had to adapt to the changing needs of their local communities. Throughout, this has often
44 required the rapid implementation of alternative or even novel strategies to meet testing
45 demands. However efforts have been hampered with staffing shortages, supply chain
46 disruptions and slow regulatory approval for alternative test protocols or testing
47 instrumentation. Combined, these challenges highlight a great need for alternative testing
48 strategies that a) utilize locally available and inexpensive testing materials, and b) are
49 easy to adopt in either existing or newly created COVID-19 testing laboratories.

50

51 Alternative testing strategies should fit seamlessly into an existing workflow of a
52 laboratory, while adhering to relevant biosafety and biosecurity requirements. Within the
53 limits imposed by the mandatory Laboratory Biosafety Guidelines for Handling and
54 Processing Specimens issued by governing bodies¹, each laboratory has their own
55 protocols when it comes to the intake and processing of infectious agents. As such,
56 adopting additional protocols to help meet mass testing needs, with limited or no flexibility
57 in the reagents, kits or instrumentation permitted for use, can result in delayed test
58 implementation due to the additional investment required or supply chain disruptions.

59

60 In an effort to increase access to COVID-19 testing by minimizing test implementation
61 challenges, we developed a freely available, open-source saliva-based RT-qPCR

62 diagnostic assay (SalivaDirect) with a simplified and flexible workflow. Key to this
63 approach was obviating the need for sample collection by trained healthcare personnel,
64 removing the requirement for specific collection devices and transport media, while
65 validating reagents and instrumentation from multiple suppliers to enable laboratories to
66 utilize their existing infrastructure, or when needed, to help circumvent supply chain
67 disruptions.

68

69 However, as SalivaDirect was made available to laboratories around the US, the diversity
70 in specimen handling processing requirements when working with potentially infectious
71 samples containing this novel coronavirus limited implementation in some sites. Upon
72 receipt of clinical samples, laboratories employ different strategies for viral inactivation
73 before processing including the addition of solvent/detergents, low pH inactivation,
74 irradiation, or heat ^{2, 3}. Previous studies have demonstrated that heat alone is capable of
75 effective viral inactivation of SARS ⁴ and Middle East Respiratory Syndrome ^{5, 6}, and more
76 recently, also for SARS-CoV-2 ^{2, 7, 8}. Given the affordability and broad availability of
77 heating sources in clinical laboratories (e.g. heating block/water bath), we sought to
78 explore additional workflows which incorporate heat-pretreatment to permit safer sample
79 handling. Using spiked and clinical saliva samples, we evaluated the effect of thermal
80 incubation of samples on the sensitivity of SARS-CoV-2 detection prior to testing in the
81 SalivaDirect assay.

82

83 **oMaterials and Methods**

84 **Ethics statement and sample collection**

85 For the spiking experiments, the use of de-identified specimens from healthy or SARS-
86 CoV-2-positive individuals was approved by the Institutional Review Board of the Yale
87 Human Research Protection Program (FWA00002571, Protocol ID. 2000027690)⁹. For
88 the clinical evaluation of the workflows, de-identified saliva samples were collected using
89 previously developed saliva self-collection protocols¹⁰, and was approved by the
90 Institutional Review Board of the Yale Human Research Protection Program (Protocol ID.
91 2000029876). For both studies, participants were informed in writing about the purpose
92 and procedure of the study, and consented to study participation through the act of
93 providing the saliva sample. All samples were transferred at room temperature to the
94 laboratory, and stored within 12 hours at -80°C until further analysis.

95

96 **Alternate workflows**

97 Saliva samples were thawed on ice and processed using the seven workflows detailed in
98 Figure 1. Each of the six new workflows (**Figures 1B and 1C**) was compared with the
99 original SalivaDirect protocol (**Figure 1A**). Each sample was first incubated at each of the
100 three different heat pretreatment conditions (65°C for 15 minutes, 95°C for 5 minutes and
101 95°C for 30 minutes) using a heating block or a thermocycler. After incubation the
102 samples were split into 2 aliquots; 10 µL was stored at 4°C until testing in RT-qPCR, and
103 50 µL was placed in a separate tube with 2.5 µL (50mg/mL) proteinase K (Thermo Fisher).
104 After vortexing for 1 minute, the samples were incubated at 95°C for 5 minutes to
105 inactivate the proteinase K. Following sample processing, 5 µL of the saliva lysates (either
106 stored at 4°C or treated with proteinase K) were tested using the SalivaDirect real-time
107 RT-qPCR assay¹¹. This assay uses primers and probes from the US CDC, targeting the

108 nucleocapsid gene (N1 2019-nCoV_N1) and the human RNase P (RP) as an extraction
109 control ¹². The RT-qPCR was performed using the Luna Universal Probe One-Step RT-
110 qPCR Kit (New England Biolabs) on the BioRad CFX96 Touch (BioRad, CA). A synthetic
111 SARS-CoV-2 RNA control from Twist Bioscience (San Francisco, CA) was diluted to 100
112 copies/ μ L and used as the positive control for N1.

113

114 **Limit of detection**

115 We performed a limit of detection confirmation study to evaluate the sensitivity of SARS-
116 CoV-2 detection when testing samples with a heat-pretreatment step. Samples were
117 prepared by spiking SARS-CoV-2-positive saliva from a healthcare worker diagnosed
118 with COVID-19 with a known virus concentration (3.7×10^4 copies/ μ L) into saliva samples
119 from healthy individuals (negative for SARS-CoV-2 RNA). Spiked saliva samples at
120 concentrations of 50, 25 and 12 copies/ μ L were tested in triplicate, and concentrations of
121 6, 3, and 1.5 copies/ μ L were tested with 20 individual replicates. All samples were tested
122 using the seven workflows depicted in **Figure 1**. The limit of detection for each workflow
123 was determined to be the lowest concentration at which at least 19/20 replicates were
124 positive for SARS-CoV-2 (cycle threshold (Ct) value <40.0).

125

126 **Workflow validation with SARS-CoV-2 clinical specimens**

127 We validated each of the different workflows using 20 de-identified clinical saliva
128 specimens which previously tested positive for SARS-CoV-2 using the standard
129 SalivaDirect workflow (Figure 1A). Each sample was processed by each of the six

130 workflows, and resulting Ct values were compared to those obtained when originally
131 tested by the standard SalivaDirect protocol.

132

133 **Data analysis**

134 The sensitivity of the different workflows were compared using repeated-measures
135 ANOVA on the Ct values of each replicate or isolate for each workflow, followed by a
136 Tukey post-hoc test to compare individual pairs of conditions. The agreement of Ct values
137 between each of the alternate workflows and original SalivaDirect protocol were assessed
138 using Pearson correlation coefficient. To compare the Ct value in the clinical samples a
139 Wilcoxon signed-rank test was performed. The negative RT-qPCR of the target gene was
140 set at the Ct value of 40 for the statistical analysis. A p value < 0.05 was considered
141 statistically significant. All analyses were conducted with GraphPad Prism 9.1.2
142 (GraphPad Software, Inc., San Diego, CA).

143

144 **Results**

145 **Limit of detection**

146 The limit of detection (LOD) for the original SalivaDirect protocol (reagents and PCR
147 instrument, depending) is as few as 1.5 copies/ μL ¹³, with the formal LOD recorded at 12
148 copies/ μL , reflecting the least sensitive combination of recommended reagents and
149 instruments ¹¹. To determine the LOD of the alternate workflows, we tested spiked saliva
150 samples at 50, 25 and 12 virus RNA copies/ μL in triplicate, all of which were detected by
151 RT-qPCR (**Table S1**). We confirmed the LOD for each workflow by testing 20 replicates
152 of spiked saliva samples at lower viral copies (6, 3 and 1.5 virus RNA copies/ μL). While

153 all 20 of the individual replicates of the spiked samples at 6 virus RNA copies/ μ L tested
154 positive for each workflow (**Figure 2, Table 1**), some workflows were more sensitive, with
155 workflows including a heat incubation step of 65°C for 15 minutes without proteinase K,
156 and 95°C for 5 minutes with or without proteinase K having a limit of detection of 3 virus
157 RNA copies/ μ L.

158

159 **Clinical evaluation of heat treatment workflows**

160 To investigate the agreement between each of the different workflows and the original
161 SalivaDirect protocol, 20 saliva samples which previously tested positive for SARS-CoV-
162 2 by SalivaDirect (Ct value range 22.16 - 38.71) were processed using each of the
163 different workflows. There was a median Ct difference in workflows of 0.92 to 6.08 across
164 each of the clinical samples (**Figure 3A**). Ct values from the N1 gene obtained from the
165 original saliva direct workflow correlated with each of the alternate workflows (Pearson r
166 > 0.9 , $p < 0.0001$) (**Figure S1, Table S2**). The workflow that was significantly less efficient
167 at detecting N1 gene than the original was 95°C for 30 minutes with the added proteinase
168 K step (Δ Ct = 1.46, $p < 0.001$).

169

170 We also investigated the impact of proteinase K on the sensitivity of each workflow
171 (**Figure 3B**). While the addition of proteinase K made no difference when the samples
172 were first incubated at 95°C for 5 minutes, the addition of proteinase K following
173 incubation at 65°C for 15 minutes resulted in an increase in sensitivity (median difference
174 in Ct value = -0.53, $p = 0.027$). When the proteinase K was added following incubation at

175 95°C for 30 minutes however, there was a decrease in sensitivity (median difference in
176 Ct value = 0.79, $p = 0.009$).

177

178 The use of the human *RNase P* (RP) control gene in the dualplex PCR helps to monitor
179 for any major degradation or inhibitors in samples. Ct values for RP were significantly
180 higher (indicating reduced detection) for all workflows except when the samples were
181 processed with incubation steps of 65°C for 15 minutes with PK, and 95°C for 5 minutes
182 with PK. None of the saliva samples had Ct values for RP over 35, the threshold for an
183 invalid sample (**Table S2**), demonstrating that none of the workflows negatively affected
184 the quality of the clinical samples.

185

186 **Discussion**

187 Saliva as a specimen type is underutilized in molecular diagnostics. Prior to 2020, almost
188 all molecular-based diagnostic tests for respiratory infections required nasopharyngeal
189 specimens (e.g aspirate or swabs) with only one test using saliva swabs for the detection
190 of cytomegalovirus ¹⁴. So following the first reports outlining the potential of saliva as a
191 reliable sample type for SARS-CoV-2 detection ^{9, 15, 16} and a means to overcome the
192 numerous challenges that labs were facing with nasopharyngeal swabs, diagnostic and
193 research laboratories alike scrambled to devise guidelines and protocols for the safe
194 handling, processing and storage of potentially infectious saliva specimens. Heating
195 samples on arrival for virus inactivation presents a straightforward approach which can
196 be easily adapted in a range of laboratory settings. As an additional benefit, heating of
197 samples decreases the viscosity of saliva samples ¹⁷, making sample pipetting easier.

198

199 In the current study we investigated the addition of thermal incubation prior to testing
200 saliva samples with the simplified RT-qPCR assay, SalivaDirect, and evaluated the effect
201 of heat pre-treatment on the sensitivity of SARS-CoV-2 detection. Although 56°C is
202 commonly used for inactivation of enveloped viruses ¹⁸, higher temperatures have been
203 used for other coronaviruses ⁶. More recently, it has been shown that SARS-CoV-2 viral
204 particles can be inactivated by incubating a sample at 65°C for 15 minutes and 95°C for
205 5 minutes before processing^{7, 8, 19}, without loss of sensitivity in nasopharyngeal swabs
206 and sera ^{2, 7}. While in the current study, we did not confirm the inactivation of SARS-CoV-
207 2 following heat pretreatment, the conditions selected were based on the literature
208 demonstrating the total inactivation of SARS-CoV-2, or, in the case of 95°C for 30 minutes
209 (workflow C), at the request of testing laboratories who were already utilizing this step
210 prior to testing by alternative methods.

211

212 For all workflows investigated, we found a limit of detection of 3 to 6 copies/μL. The
213 robustness of the detection of the N1 gene in saliva has been demonstrated previously,
214 with no significant decrease in sensitivity when exposed to moderate heat ^{10, 20}.
215 Additionally, proteinase K also did not significantly affect the overall sensitivity of detection
216 of the N1 gene (paired t test, $p = 0.247$). Rather, at the lower incubation temperature
217 (65°C for 15 minutes), addition of proteinase K marginally increased the sensitivity of
218 detection as compared to samples processed without proteinase K. It is possible that,
219 while 65°C alone can effectively inactivate SARS CoV-2, this is not as effective at
220 “extracting” all of the virus RNA for RT-qPCR detection. Conversely, the addition of the

221 proteinase K step to samples incubated at 95°C for 30 minutes significantly decreased
222 the sensitivity of both N1 and RNase P detection when compared to the original
223 SalivaDirect protocol. However, while RP is used as an internal control, the minor
224 differences observed would not affect the outcome of the assay. Proteinase K degrades
225 RNases and assists in preserving RNA integrity, hence it is commonly used in the
226 processing of samples for molecular assays, especially in various extraction-free
227 workflows^{21, 22}. Extraction-free workflows with saliva is no exception, and has been
228 incorporated into many saliva-based extraction-free molecular assays ²³⁻²⁶, including
229 SalivaDirect.

230

231 The addition of alternate workflows to an already flexible testing framework further
232 support the rapid implementation of the SalivaDirect RT-qPCR assay in diagnostic and
233 research laboratories looking to improve access to SARS-CoV-2 testing in their local
234 communities. Importantly, with the addition of pre-treatment heat steps, these expanded
235 workflows help to prevent the exposure of laboratory personnel directly or indirectly
236 handling potentially SARS-CoV-2-infected samples, while providing flexibility of
237 adaptation into their existing standard operating procedures. One of the unique attributes
238 of SalivaDirect is it is validated with materials from multiple vendors, to minimize the risk
239 of supply chain issues. The option of omitting proteinase K treatment makes this flexible
240 framework even less vulnerable to supply shortages, and more affordable for laboratories
241 - and thus importantly, to their patients. This is especially important for the implementation
242 of mass testing strategies in resource-poor areas, or in low-to-middle income countries

243 which continue to suffer the brunt of the reagent and laboratory consumables shortages
244 during the pandemic.

245

246 **Data Availability**

247 All of the data generated from this study is in the Supplementary information.

248

249 **Author contributions**

250 A.L.W. conceived the study. O.M.A. and R.E. assisted with the coordination and
251 execution of the study. R.E., M.E.P., C.K. and T.A. coordinated sample collection. M.I.B.,
252 I.M.O, D.Y-C., O.M.A. and N.V. performed the diagnostic tests. O.M.A. and N.V. analyzed
253 the data. O.M.A. assisted with the design of the statistical analysis. O.M.A., N.V., and
254 A.L.W. wrote and edited the manuscript.

255

256 **Acknowledgements**

257 We thank the study participants for their time and cooperation. This work was funded by
258 Tempus Labs, Inc (A.L.W), Yale Center for Clinical Investigation TL1 TR001864 (M.E.P.)
259 and Fast Grant from Emergent Ventures at the Mercatus Center at George Mason
260 University (A.L.W).

261 **References**

- 262 1. CDC: Interim Laboratory Biosafety Guidelines for Handling and Processing
263 Specimens Associated with Coronavirus Disease 2019 (COVID-19).
264 <https://www.cdc.gov/coronavirus/2019-ncov/lab/lab-biosafety-guidelines.html>.
265 Last Accessed 2021/11/30.
- 266 2. Patterson EI, Prince T, Anderson ER, Casas-Sanchez A, Smith SL, Cansado-
267 Utrilla C, Solomon T, Griffiths MJ, Acosta-Serrano Á, Turtle L, Hughes GL:
268 Methods of Inactivation of SARS-CoV-2 for Downstream Biological Assays. J
269 Infect Dis 2020, 222:1462-1467.
- 270 3. Darnell MER, Subbarao K, Feinstone SM, Taylor DR: Inactivation of the
271 coronavirus that induces severe acute respiratory syndrome, SARS-CoV. J Virol
272 Methods 2004, 121:85-91.
- 273 4. Pagat A-M, Seux-Goepfert R, Lutsch C, Lecouturier V, Saluzzo J-F, Kusters IC:
274 Evaluation of SARS-Coronavirus Decontamination Procedures. Appl Biosaf 2007,
275 12:100-108.
- 276 5. Kampf G, Voss A, Scheithauer S: Inactivation of coronaviruses by heat. J Hosp
277 Infect 2020, 105:348-349.
- 278 6. Leclercq I, Batéjat C, Burguière AM, Manuguerra J-C: Heat inactivation of the
279 Middle East respiratory syndrome coronavirus. Influenza Other Respi Viruses
280 2014, 8:585-586.
- 281 7. Batéjat C, Grassin Q, Manuguerra J-C, Leclercq I: Heat inactivation of the severe
282 acute respiratory syndrome coronavirus 2. J Biosaf Biosecur 2021, 3:1-3.

- 283 8. Smyrlaki I, Ekman M, Lentini A, Rufino de Sousa N, Papanicolaou N, Vondracek
284 M, Aarum J, Safari H, Muradrasoli S, Rothfuchs AG, Albert J, Högberg B, Reinius
285 B: Massive and rapid COVID-19 testing is feasible by extraction-free SARS-CoV-
286 2 RT-PCR. *Nat Commun* 2020, 11:4812.
- 287 9. Wyllie AL, Fournier J, Casanovas-Massana A, Campbell M, Tokuyama M,
288 Vijayakumar P, Warren JL, Geng B, Muenker MC, Moore AJ, Vogels CBF, Petrone
289 ME, Ott IM, Lu P, Venkataraman A, Lu-Culligan A, Klein J, Earnest R, Simonov M,
290 Datta R, Handoko R, Naushad N, Sewanan LR, Valdez J, White EB, Lapidus S,
291 Kalinich CC, Jiang X, Kim DJ, Kudo E, Linehan M, Mao T, Moriyama M, Oh JE,
292 Park A, Silva J, Song E, Takahashi T, Taura M, Weizman O-E, Wong P, Yang Y,
293 Bermejo S, Odio CD, Omer SB, Dela Cruz CS, Farhadian S, Martinello RA, Iwasaki
294 A, Grubaugh ND, Ko AI: Saliva or Nasopharyngeal Swab Specimens for Detection
295 of SARS-CoV-2. *N Engl J Med* 2020, 383:1283-1286.
- 296 10. Allicock OM, Petrone ME, Yolda-Carr D, Breban M, Walsh H, Watkins AE,
297 Rothman JE, Farhadian SF, Grubaugh ND, Wyllie AL: Usability of saliva collection
298 devices for SARS-CoV-2 diagnostics. *medRxiv* 2021.
- 299 11. Vogels CBF, Watkins AE, Harden CA, Brackney DE, Shafer J, Wang J, Caraballo
300 C, Kalinich CC, Ott IM, Fauver JR, Kudo E, Lu P, Venkataraman A, Tokuyama M,
301 Moore AJ, Muenker MC, Casanovas-Massana A, Fournier J, Bermejo S, Campbell
302 M, Datta R, Nelson A, Yale IRT, Dela Cruz CS, Ko AI, Iwasaki A, Krumholz HM,
303 Matheus JD, Hui P, Liu C, Farhadian SF, Sikka R, Wyllie AL, Grubaugh ND:
304 SalivaDirect: A simplified and flexible platform to enhance SARS-CoV-2 testing
305 capacity. *Med (N Y)* 2021, 2:263-280.e266.

- 306 12. CDC: Research Use Only 2019-Novel Coronavirus (2019-nCoV) Real-time RT-
307 PCR Primers and Probes. [https://www.cdc.gov/coronavirus/2019-ncov/lab/rt-pcr-](https://www.cdc.gov/coronavirus/2019-ncov/lab/rt-pcr-panel-primer-probes.html)
308 [panel-primer-probes.html](https://www.cdc.gov/coronavirus/2019-ncov/lab/rt-pcr-panel-primer-probes.html). Last Accessed 2021/08/09.
- 309 13. FDA: SalivaDirect - EUA Summary. <https://www.fda.gov/media/141192/>. Last
310 Accessed 2021/12/21.
- 311 14. FDA: FDA authorizes first test to aid in detecting a type of herpes virus in newborns
312 called cytomegalovirus. [https://www.fda.gov/news-events/press-](https://www.fda.gov/news-events/press-announcements/fda-authorizes-first-test-aid-detecting-type-herpes-virus-newborns-called-cytomegalovirus)
313 [announcements/fda-authorizes-first-test-aid-detecting-type-herpes-virus-](https://www.fda.gov/news-events/press-announcements/fda-authorizes-first-test-aid-detecting-type-herpes-virus-newborns-called-cytomegalovirus)
314 [newborns-called-cytomegalovirus](https://www.fda.gov/news-events/press-announcements/fda-authorizes-first-test-aid-detecting-type-herpes-virus-newborns-called-cytomegalovirus). Last Accessed 2021/12/21.
- 315 15. Hanson KE, Barker AP, Hillyard DR, Gilmore N, Barrett JW, Orlandi RR, Shakir
316 SM: Self-Collected Anterior Nasal and Saliva Specimens versus Health Care
317 Worker-Collected Nasopharyngeal Swabs for the Molecular Detection of SARS-
318 CoV-2. J Clin Microbiol 2020, 58.
- 319 16. Byrne RL, Kay GA, Kontogianni K, Aljayyousi G, Brown L, Collins AM, Cuevas
320 LE, Ferreira DM, Fraser AJ, Garrod G, Hill H, Hughes GL, Menzies S, Mitsi E,
321 Owen SI, Patterson EI, Williams CT, Hyder-Wright A, Adams ER, Cubas-Atienzar
322 AI: Saliva Alternative to Upper Respiratory Swabs for SARS-CoV-2 Diagnosis.
323 Emerg Infect Dis 2020, 26:2770-2771.
- 324 17. Sahajpal NS, Mondal AK, Ananth S, Njau A, Ahluwalia P, Newnam G, Lozoya-
325 Colinas A, Hud NV, Kota V, Ross TM, Reid MD, Fulzele S, Chaubey A, Hegde M,
326 Rojiani AM, Kolhe R: SalivaSTAT: Direct-PCR and Pooling of Saliva Samples
327 Collected in Healthcare and Community Setting for SARS-CoV-2 Mass
328 Surveillance. Diagnostics (Basel) 2021, 11.

- 329 18. Gröner A, Broumis C, Fang R, Nowak T, Popp B, Schäfer W, Roth NJ: Effective
330 inactivation of a wide range of viruses by pasteurization. *Transfusion* 2018, 58:41-
331 51.
- 332 19. Burton J, Love H, Richards K, Burton C, Summers S, Pitman J, Easterbrook L,
333 Davies K, Spencer P, Killip M, Cane P, Bruce C, Roberts ADG: The effect of heat-
334 treatment on SARS-CoV-2 viability and detection. *J Virol Methods* 2021,
335 290:114087.
- 336 20. Ott IM, Strine MS, Watkins AE, Boot M, Kalinich CC, Harden CA, Vogels CBF,
337 Casanovas-Massana A, Moore AJ, Muenker MC, Nakahata M, Tokuyama M,
338 Nelson A, Fournier J, Bermejo S, Campbell M, Datta R, Dela Cruz CS, Farhadian
339 SF, Ko AI, Iwasaki A, Grubaugh ND, Wilen CB, Wyllie AL, Yale IRT: Stability of
340 SARS-CoV-2 RNA in Nonsupplemented Saliva. *Emerg Infect Dis* 2021, 27:1146-
341 1150.
- 342 21. Espy MJ, Patel R, Paya CV, Smith TF: Comparison of three methods for extraction
343 of viral nucleic acids from blood cultures. *J Clin Microbiol* 1995, 33:41-44.
- 344 22. Sung H, Yong D, Ki C-S, Kim J-S, Seong M-W, Lee H, Kim M-N: Comparative
345 evaluation of three homogenization methods for isolating Middle East respiratory
346 syndrome coronavirus nucleic acids from sputum samples for real-time reverse
347 transcription PCR. *Ann Lab Med* 2016, 36:457-462.
- 348 23. Azmi I, Faizan MI, Kumar R, Raj Yadav S, Chaudhary N, Kumar Singh D, Butola
349 R, Ganotra A, Datt Joshi G, Deep Jhingan G, Iqbal J, Joshi MC, Ahmad T: A Saliva-
350 Based RNA Extraction-Free Workflow Integrated With Cas13a for SARS-CoV-2
351 Detection. *Front Cell Infect Microbiol* 2021, 11:632646.

- 352 24. Mahmoud SA, Ganesan S, Ibrahim E, Thakre B, Teddy JG, Raheja P, Abbas WZ:
353 Evaluation of RNA Extraction-Free Method for Detection of SARS-CoV-2 in
354 Salivary Samples for Mass Screening for COVID-19. Biomed Res Int 2021, 2021.
- 355 25. de Oliveira CM, Brochi L, Scarpelli LC, Lopes ACW, Levi JE: SARS-CoV-2 saliva
356 testing is a useful tool for Covid-19 diagnosis. J Virol Methods 2021:114241.
- 357 26. Genoud V, Stortz M, Waisman A, Berardino BG, Verneris P, Dansey V, Salvatori M,
358 Remes Lenicov F, Levi V: Extraction-free protocol combining proteinase K and
359 heat inactivation for detection of SARS-CoV-2 by RT-qPCR. PLoS One 2021,
360 16:e0247792.
- 361

362 Tables

363 **Table 1. The number of replicates of spiked saliva samples which were considered positive**
364 **following testing in the alternative workflows including heat pre-treatment with or without**
365 **treatment with proteinase K (PK).**

Concentration of spiked saliva (virus RNA copies/ μ L)	65°C for 15 minutes		95°C for 5 minutes		95°C for 30 minutes	
	With PK	Without PK	With PK	Without PK	With PK	Without PK
6 copies/ μ L	20/20*	20/20	20/20	20/20	20/20	20/20
3 copies/ μ L	17/20	20/20	19/20	19/20	12/20	15/20
1.5 copies/ μ L	15/20	17/20	10/20	15/20	8/20	14/20

366 *Concentrations where at least 19/20 replicates tested positive (indicating the assay limit of detection) are
367 shown in bold.

368

369 Figures

370 **Figure 1. Alternative SalivaDirect workflows including heat-pretreatment prior to**
371 **sample processing.** In the original SalivaDirect protocol, (A) raw saliva is combined with
372 proteinase K then followed by heat-inactivation of the proteinase K and testing in RT-
373 qPCR. The alternate workflows include an initial heat treatment step (65°C for 15 minutes,
374 95°C for 5 minutes or 95°C for 30 minutes), followed by either (B) testing by RT-qPCR
375 directly or (C) the addition and inactivation of proteinase K prior to testing by RT-qPCR.
376 (Figure created with BioRender.com)


377




378 **Figure 2. Comparison of the sensitivity of the 6 alternate workflows of the**
379 **SalivaDirect RT-qPCR saliva-based assay for SARS-CoV-2 detection.** Each
380 alternative workflow was evaluated by processing spiked positive saliva at (A) 6, (B) 3,

381 and (C) 1.5 copies/ μ L in 20 replicates, and comparing the CT values as a proxy for
382 workflow sensitivity. Solid lines indicate the median Ct values targeting the N1 gene. The
383 dashed line indicates the detection limit at 40 Ct with samples falling below the dashed
384 line considered negative for SARS-CoV-2. The differences between each of the
385 workflows and the original SalivaDirect protocol were compared by a Wilcoxon test
386 ($p < 0.05$, * = 0.03, ** = 0.001). Data used to make this figure can be found in **Table S1**.
387 *Abbreviations: Ct, cycle threshold; ND, not detected; PK, proteinase K.*


388

389 **Figure 3. Detection of SARS-CoV-2 RNA in positive clinical saliva samples across**
390 **the 7 different workflows.** Clinical saliva samples positive for SARS-CoV-2 were used
391 to compare the sensitivities in detection across the 7 workflows. (A) Ct values for each of
392 the 20 clinical samples processed with the different workflows. The solid lines indicate the
393 median Ct values and 95% CI for each sample across the different workflows. Each dot
394 represents an individual replicate of each of the 20 clinical samples as indicated by the
395 dash on the x-axis. (B) We evaluated the effect of proteinase K on the sensitivity of
396 detection between each of 3 different heat treatment conditions by a Wilcoxon test ($p <$
397 0.05). Matched clinical samples are represented by the solid black line between those
398 processed without proteinase K (blue dots), and those with proteinase K (green dots).
399 The area below the dotted line indicates the detection threshold for the N1 gene. Data
400 used to make this figure can be found in Table S2. (*, $p = 0.027$; **, $p = 0.009$)
401 *Abbreviations: Ct, cycle threshold; ND, not detected; PK, proteinase K.*





- 65°C, 15 mins
- 65°C, 15 mins + PK
- 95°C, 5 mins
- 95°C for 5 minutes, PK
- 95°C, 30 mins
- 95°C for 30 minutes, PK
- SalivaDirect

A**B**